Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
HFpEF治療超越SGLT2-Is:GLP-1 RA的添加是否能改善糖尿病患者的心臟代謝風險和結果?
Int J Mol Sci 2022-12-22
Obesity, heart failure with preserved ejection fraction, and the role of glucagon-like peptide-1 receptor agonists.
肥胖、保留射血分數心臟衰竭,以及胰高血糖素樣肽-1 受體激動劑的作用。
ESC Heart Fail 2024-03-29
Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF.
超越減重:胰高血糖素類治療在心臟代謝性 HFpEF 中新興的角色。
Curr Opin Cardiol 2024-04-04
New Mechanisms to Prevent Heart Failure with Preserved Ejection Fraction Using Glucagon-like Peptide-1 Receptor Agonism (GLP-1 RA) in Metabolic Syndrome and in Type 2 Diabetes: A Review.
利用胰高血糖素樣肽-1受體激動劑(GLP-1 RA)在代謝綜合徵和第2型糖尿病中預防保留射血分數心力衰竭的新機制:一項回顧。
Int J Mol Sci 2024-04-29
Semaglutide in Heart Failure With Preserved Ejection Fraction: Exploring Recent Evidence in Therapeutic Potential for the Obese Population.
Semaglutide在保留射血分數心衰竭中的應用:探討對肥胖人群的治療潛力的最新證據。
Cardiol Rev 2024-05-17
Role of glucagon-like peptide-1 agonists in obesity and heart failure with preserved ejection fraction.
GLP-1激動劑在肥胖和保留射血分數心衰中的作用。
Eur Heart J Suppl 2024-06-13
GLP-1 Receptor Agonists Among Patients With Overweight or Obesity, Diabetes, and HFpEF on SGLT2 Inhibitors.
在使用 SGLT2 抑制劑的超重或肥胖、糖尿病及 HFpEF 患者中,GLP-1 受體激動劑的應用。
JACC Heart Fail 2024-08-29